Joseph Munyi, a Kenyan citizen, has been living with HIV for 8 years and, much like other HIV patients, is unemployed. He has been receiving his medication free of charge on account of government programmes and outreach programmes of Medicine Sans Frontieres. His medication comes in the form of generic drugs. However, this situation may not last long as economic interests of few may end up impeding many a public spirited...

Having watched from the ringside for many years now, I have no doubt in advising that the steering wheel must be firmly grasped by the government and direction given to policies that should be stable for at least the medium term. This is crucial for the growth of Indian pharma, a $20-billion industry growing at an average of 12% considering both domestic and export arenas. Price control: The biggest and most...

Doctors across India who encounter patients with tuberculosis will have to disclose the identity, age, sex, and address of each patient to local health authorities under an order issued this week by the Union health ministry. The health ministry said today that it is essential to have complete information as part of its efforts to ensure that patients receive proper diagnosis and therapy and to curb the emergence and spread of...

The debate about essential-medicine pricing and access in India illustrates the difficulties inherent in establishing policies that serve conflicting public interests in achieving goals such as caring well and ensuring safety for all, while also pursuing financially-sustainable success in scientific innovation and trade. It highlights problems facing those interested in continuing drug and vaccines development and ensuring that, once marketed, such products contribute effectively to improving public health. Modern pharmaceuticals...

-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...